» Authors » C Vasconcelos-Nobrega

C Vasconcelos-Nobrega

Explore the profile of C Vasconcelos-Nobrega including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 5
Citations 60
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Esteves F, Cruz R, Vasconcelos-Nobrega C, Santos C, Ferreira A, Petrovic T, et al.
Transbound Emerg Dis . 2018 May; 65(6):1553-1556. PMID: 29761919
A few years after the initial 2011 large scale Schmallenberg virus (SBV) epidemic that affected Europe, a subsequent decrease in new SBV infections was observed presumably associated with natural substitution...
2.
Oliveira P, Gil da Costa R, Vasconcelos-Nobrega C, Arantes-Rodrigues R, Pinto-Leite R
Expert Opin Drug Discov . 2016 Apr; 11(6):599-607. PMID: 27077499
Introduction: Urinary bladder cancer (UBC) is the second most frequent malignancy of the urinary system and the ninth most common cancer worldwide, affecting individuals over the age of 65. Several...
3.
Vasconcelos-Nobrega C, Costa C, Vala H, Colaco A, Santos L, Lopes C, et al.
Urol Int . 2013 Apr; 91(4):462-6. PMID: 23548313
Background: E-cadherin and β-catenin are adhesion molecules that promote integrity and stability of the urothelium. A decrease in their expression is associated with more aggressive tumour phenotypes with the ability...
4.
Vasconcelos-Nobrega C, Colaco A, Lopes C, Oliveira P
In Vivo . 2012 Jul; 26(4):727-39. PMID: 22773588
Experimental urinary bladder tumours have been proposed as a useful model for the study of urinary bladder carcinogenesis, as well as for evaluating new therapeutic strategies. Consequently, the administration of...
5.
Vasconcelos-Nobrega C, Colaco A, Santos L, Vala H, Palomino L, Lopes C, et al.
Anticancer Res . 2011 May; 31(5):1637-42. PMID: 21617220
Background: The purpose of this study was to determine the efficacy of a combination of gemcitabine and sirolimus in a mouse model of invasive bladder cancer. Materials And Methods: Gemcitabine...